Treatment of Chemotherapy-related Hiccups With Baclofen

• Status: Unknown status
• Trial end date: 2019-12-20
• Target enrollment: 0
• Participant gender: All

Summary

Hiccup is one of the common side effects of chemotherapy. Intractable hiccups seriously affect patients' rest and eating, reduce the quality of life, and increasingly attract the attention of oncologists. At present, drugs or methods for treating chemotherapy-related hiccups are generally ineffective, with short remission time, serious adverse reactions, and unsatisfactory clinical effects. Baclofen produces skeletal muscle relaxation and was originally used in patients with spinal cord injury, and has since been used to treat intractable hiccups caused by diaphragmatic spasm. This study was an open-label, randomized, prospective study comparing the efficacy and adverse effects of baclofen versus metoclopramide in the treatment of chemotherapy-related hiccups. Patients with hiccup after chemotherapy were randomly divided into two groups. One group was treated with baclofen and the other group was treated with metoclopramide. The efficacy and adverse reactions of the two groups were compared.Ineffective in the two groups will cross to another group and then observe the efficacy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital of Nanchang University
• Treatments: Baclofen; Metoclopramide

Criteria

Inclusion Criteria:

• Pathological diagnosis of malignant tumors;PS score 0 ~ 3 points;

• Hiccups occurred within 48 h after chemotherapy, lasting longer than 2 h.

Exclusion Criteria:

• No serious heart, brain, lung, kidney and other diseases, no gastrointestinal bleeding, no serious obstacles to blood clotting;

• Blood routine and normal electrolyte of liver and kidney function before chemotherapy.